Aug 13, 2023 · Ondansetron (Zofran) is used to prevent nausea and vomiting that may be caused by surgery or by medicine to treat cancer. Includes Ondansetron side effects, interactions and indications.

Mar 1, 2025 · For oral dosage forms (oral disintegrating tablets, solution, or tablets): For prevention of moderate nausea and vomiting after treatment with cancer medicines: Adults and children 12 years of age and older—At first, 8 milligrams (mg) taken 30 minutes before starting cancer treatment.

Jul 3, 2024 · Ondansetron is available in the following dosage forms that are taken by mouth. 4 mg and 8 mg orally disintegrating tablets; 4 mg/5 mL oral solution; 4 mg, 8 mg, and 24 mg oral tablets

Sep 24, 2024 · Recommended dose: 8 mg orally 3 times a day. The injection formulation should be diluted in 50 mL prior to IV administration. This drug should be used to prevent nausea and vomiting associated with moderately to highly emetogenic chemotherapy. No …

Aug 5, 2021 · Form: orally disintegrating tablet; Strengths: 4 mg, 8 mg; Dosage for prevention of nausea and vomiting caused by chemotherapy

Dec 12, 2024 · A typical ondansetron dose is 8 mg to 24 mg for adults and adolescents and 4 mg for children under the age of 12. Doses over 24 mg per day aren’t recommended. Oral ondansetron comes as a tablet, an orally disintegrating tablet, and an oral solution.

5 days ago · For children who are receiving chemotherapy and are 4 to 11 years old, the typical dosage of ondansetron oral forms is 4 mg taken 30 minutes before chemotherapy starts. At 4 hours later, another 4 ...

Dec 29, 2024 · Ondansetron orally disintegrating tablets are indicated for the prevention of nausea and vomiting associated with: highly emetogenic cancer chemotherapy, including cisplatin greater than or equal ... 2.1 Dosage - The recommended dosage regimens for adult and pediatric patients are described in Table 1 and Table 2, respectively.

May 8, 2023 · Pharmacodynamics - Ondansetron is a selective 5-HT3 receptor antagonist. While its mechanism of action has not been fully characterized, ondansetron is not a dopamine-receptor antagonist ... Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin ≥50 mg/m2.

8 mg administered 30 minutes before the start of chemotherapy, with a subsequent 8 mg dose 8 hours after the first dose. Then administer 8 mg twice a day (every 12 hours) for 1 to 2 days after completion of chemotherapy. For total body irradiation: 8 mg administered 1 to 2 hours before each fraction of radiotherapy each day.